u/pwirk794

The author claims Cybin (HELP) is highly undervalued relative to other psychedelic stocks and has Phase 3 data coming with a trial design modeled exactly like CMPS, which had FDA breakthrough designation for Phase 2. They argue its deuterated psilocybin is more stable and predictable, requiring only 3-hour therapy sessions twice a year versus Spravato's 2x weekly sessions, making it a superior commercial profile. The stated catalyst is the Phase 3 data readout, which the author expects to drive the stock higher before CMPS approval. Main risk implied is clinical/regulatory failure of the Phase 3 program.